Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit

Abstract

The invention concerns nutritional compositions with fucosyllactose for use in stimulation of NK cells. The composition is suitable for infants.

1 - 9 . (canceled) 
     
     
         10 . A method for treating and/or preventing viral infections caused by orthomyxoviridae, comprising administering to a mammal in need thereof an enteral composition comprising 2′-fucosyllactose, wherein the composition is not human milk. 
     
     
         11 . The method according to  claim 10 , wherein the orthomyxoviridae comprise influenza virus, herpesviridae, rotavirus, cytomegalovirus, respiratory syncytial virus, human imunodeficiency virus and/or rhinovirus. 
     
     
         12 . The method according to  claim 10 , wherein the mammal suffers from common cold, flu, measles, chicken pox, viral gastro-enteritis, HIV infection and/or a viral respiratory tract infection. 
     
     
         13 . The method according to  claim 10 , wherein the mammal is an infant, HIV patient, elderly and/or oncology patient. 
     
     
         14 . The method according to  claim 10 , wherein the mammal is a human. 
     
     
         15 . The method according to  claim 14 , wherein the mammal is a human infant. 
     
     
         16 . The method according to  claim 13 , wherein the human is a HIV patient, an elderly person and/or an oncology patient. 
     
     
         17 . The method according to  claim 10 , wherein the composition further comprises at least one of beta-galacto-oligosaccharides, fructo-oligosaccharides and uronic acid oligosaccharides. 
     
     
         18 . The method according to  claim 10 , wherein the composition comprises 0.07 to 1 wt % fucosyllactose, based on dry weight of the composition. 
     
     
         19 . The method according to  claim 10 , wherein the composition further comprises, based on total energy of the composition, 5 to 50% protein, 15 to 85% digestible carbohydrates and 5 to 50% fat. 
     
     
         20 . A method for enhancing a vaccination response, comprising administering to a mammal an enteral composition comprising 2′-fucosyllactose. 
     
     
         21 . The method according to  claim 20 , wherein the response to vaccination with a viral antigen is enhanced. 
     
     
         22 . An infant formula comprising 2′-fucosyllactose.